BNP rises in heart failure because stretched, overworked heart muscle cells release it as a distress signal. When the heart can’t pump efficiently, blood backs up and increases pressure inside the ventricles. That pressure physically stretches the walls of the heart, and the stretched cells respond by producing and secreting BNP into the bloodstream. The worse the heart failure, the greater the stretch, and the higher the BNP level climbs.
How Heart Muscle Cells Produce BNP
BNP stands for B-type natriuretic peptide. Heart muscle cells manufacture it as a larger precursor molecule called proBNP, a 108-amino-acid protein. Once released into the bloodstream, enzymes called corin and furin split proBNP into two pieces: the active hormone BNP (32 amino acids) and an inactive fragment called NT-proBNP (76 amino acids). Both pieces circulate in the blood and both are measured in clinical tests, though they behave differently once released.
The primary trigger for this whole process is mechanical stretch of the ventricular wall. But stretch isn’t the only signal. Hormones that are already elevated in heart failure, including angiotensin II and endothelin-1, also ramp up BNP production inside heart cells. These signals converge on a common pathway that activates a protein called GATA4, which acts as a master switch for turning on the BNP gene. This means the sicker the heart gets, the more signals pile up telling it to produce BNP.
What BNP Actually Does in the Body
BNP isn’t just a passive marker of heart failure. It’s the body’s attempt to fight back against the fluid overload and high pressures that come with a failing heart. It performs several protective functions: it tells the kidneys to excrete more sodium and water (reducing blood volume), it relaxes blood vessels (lowering blood pressure), and it suppresses the renin-angiotensin-aldosterone system, which is the hormonal cascade that otherwise drives the body to retain salt and constrict blood vessels.
In higher amounts, BNP lowers systemic vascular resistance, raises cardiac output, and reduces pressure in the lungs. Think of it as the heart’s built-in counterbalance to the vicious cycle of fluid retention and rising pressures. The problem is that in advanced heart failure, the protective effects of BNP aren’t enough to overcome the disease. The heart keeps stretching, keeps producing more BNP, and levels climb higher and higher as the condition worsens.
BNP vs. NT-proBNP in Blood Tests
When your doctor orders a “BNP test,” you may actually receive a test for either BNP or NT-proBNP. Both come from the same parent molecule, but they have important differences. BNP has a half-life of about 20 minutes, meaning it’s cleared from the blood quickly. NT-proBNP lingers much longer, with a half-life of about 120 minutes. This is because BNP is actively broken down by an enzyme called neprilysin and removed by specific receptors, while NT-proBNP lacks those clearance routes and is filtered out mainly by the kidneys.
That kidney-dependent clearance matters. If your kidney function is impaired, NT-proBNP levels can be disproportionately elevated, which complicates interpretation. In patients with worsening heart failure, neprilysin activity may also increase, breaking down active BNP faster and potentially causing BNP levels to underestimate disease severity compared to NT-proBNP.
What the Numbers Mean
For BNP, levels below 100 pg/mL make heart failure unlikely. Levels between 100 and 400 pg/mL suggest possible heart failure, especially if symptoms and history line up. Levels above 400 pg/mL point strongly toward heart failure.
NT-proBNP thresholds are higher and vary by age. For people under 50, levels above 450 pg/mL suggest heart failure. Between ages 50 and 75, that threshold rises to 900 pg/mL, and for those over 75, the cutoff is 1,800 pg/mL. NT-proBNP above 1,000 pg/mL has been linked to more severe heart failure and a worse outlook regardless of age. These tests are generally better at ruling heart failure out than ruling it in. A low BNP or NT-proBNP in someone with unexplained shortness of breath makes heart failure a much less likely explanation.
The 2022 guidelines from the American College of Cardiology and American Heart Association specifically note that elevated natriuretic peptides help confirm the diagnosis when the heart’s pumping ability is only mildly reduced or even preserved. In these subtler forms of heart failure, where physical exam findings can be ambiguous, BNP and NT-proBNP provide objective evidence that pressures inside the heart are abnormally high.
Higher Levels Signal Greater Risk
BNP levels don’t just help with diagnosis. They also predict outcomes. In a large study tracking over 19,000 patients across more than 90,000 person-years, BNP and age were the two strongest predictors of death in both heart failure and non-heart failure patients. A BNP of 400 pg/mL was associated with roughly a 21% chance of dying within three years for someone with heart failure and 19% for someone without a prior heart failure diagnosis. A much lower BNP of 55 pg/mL corresponded to a three-year mortality of about 13% in heart failure patients and 10% in those without it.
Moving from the 25th to the 75th percentile in BNP levels roughly doubled the risk of death in both groups. This gradient is why doctors track BNP over time, not just at a single visit. A rising BNP often signals worsening function even before symptoms change noticeably, while a falling BNP after treatment suggests the heart is under less strain.
Why Obesity Can Mask Elevated BNP
One important complication: BNP levels run lower in people with higher body weight, and this can cause misleading results. In both forms of heart failure, BNP decreases as BMI increases. Among morbidly obese patients hospitalized for acute heart failure, about 1 in 8 had BNP levels below 100 pg/mL, the threshold normally used to rule heart failure out. For morbidly obese patients with the preserved-ejection-fraction type of heart failure specifically, that ratio was closer to 1 in 7.
Several explanations exist for this pattern. Fat tissue expresses more of the receptors that clear BNP from the bloodstream, effectively acting as a sponge. There may also be impaired production or secretion of BNP from the heart muscle itself in obese individuals. Whatever the mechanism, the clinical implication is straightforward: a “normal” BNP in a significantly overweight person with symptoms of heart failure doesn’t reliably exclude the diagnosis. Doctors need to interpret the number in context, not in isolation.
BNP in the Bigger Picture of Heart Failure
BNP elevation in heart failure is both a consequence of disease and a compensatory response to it. The failing heart stretches, the stretched cells release BNP, and BNP tries to reduce the burden by offloading fluid and relaxing blood vessels. But as the disease progresses, the heart produces ever-increasing amounts that overwhelm the body’s ability to restore balance. That escalating production is precisely what makes BNP so valuable as a biomarker: it tracks the severity of the underlying problem in real time, rising and falling as pressures inside the heart change. It gives clinicians a window into what’s happening at the level of the heart wall itself, translating mechanical stress into a measurable number.